ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Trial Profile

ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Bendamustine (Primary) ; Lenalidomide; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON110FL-GLSG-NCRI; ReBeL
  • Most Recent Events

    • 18 Aug 2015 Planned End Date changed from 1 Oct 2025 to 1 Oct 2015, as reported by United Kingdom Clinical Research Network.
    • 18 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2025 as reported by UK Clinical Trials Register record.
    • 13 Jul 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2011-000097-56).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top